Log In
BCIQ
Print this Print this
 

rHuEPO

  Manage Alerts
Collapse Summary General Information
Company XTL Biopharmaceuticals Ltd.
DescriptionRecombinant human erythropoietin (rHuEPO)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation U.S. - Orphan Drug (Treat multiple myeloma (MM))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today